Altruist Bio
Hangzhou, China altruistbio.com From their website, Nov 2026
- GMP
Work here? Claim this listing
About
Altruist Biologics is a CDMO that provides development and GMP manufacturing services for biologics and bioconjugates, including antibodies, fusion proteins, recombinant proteins, and antibody drug conjugates. It serves customers developing and commercializing these products from early development through commercial supply, with facilities in Suzhou and Hangzhou, China.
Altruist Bio is a CDMO in Hangzhou, China, founded in 2022. It lists 9 services, including Mammalian Cell Line Development, Process Development and Formulation Development. It names GMP on its listing.
Services
Mammalian Cell Line Development
Develops high-yield, stable mammalian cell lines and establishes primary, master, and working cell banks under GMP conditions.
Cell line development
Process Development
Provides cell culture process development, scale-up, process characterization, validation, and toxicology and clinical sample preparation.
Formulation Development
Develops robust formulations for drug substance and drug product, including container closure, in-use stability, and high-concentration formulation work.
Analytical Method Development
Develops, transfers, and validates analytical methods for CMC requirements, release testing, characterization, and stability studies.
GMP Drug Substance Manufacturing
Provides clinical- and commercial-scale GMP drug substance manufacturing for biologics.
GMP Drug Product Manufacturing
Provides clinical- and commercial-scale GMP drug product manufacturing.
Labeling & Packaging
Offers labeling and packaging services as part of manufacturing support.
ADC and Bioconjugation Development
Develops antibody drug conjugates and other bioconjugates, including payload, linker, and assembly work.
1 more services
- Regulatory Support
- Turnaround
- 10 weeks from DNA to Primary Cell Bank generation
- Six or more months to evaluate final formulation
How to order from Altruist Bio
Turnaround they state: 10 weeks from DNA to Primary Cell Bank generation; Six or more months to evaluate final formulation. They take requests through the contact form on their website. You can contact them directly from this page, or request a quote through Midgard.
Capabilities
- Assays and studies
- ADCs
- Antibodies
- Process development
- Analytical development
- Bispecifics
- CHO
14 more
- Bioreactors
- Stability studies
- Bioassays
- Binding ELISA
- Peptide mapping
- CE-SDS
- SEC
- icIEF
- CEX
- Residual DNA testing
- HCP testing
- Protein A testing
- Comparability testing
- Stability testing
- Scale and capacity
- 50 L to 500 L non-GMP pilot scales
- 1 kL to 20 kL
- 1,000 L to 20,000 L
- 4 x 20,000 L stainless steel bioreactors
- 232,000 liters expected total capacity by 2026
- Therapeutic areas
- Cancer
- Cardiovascular disease
- Metabolic disease
- Autoimmune disease
- Eye disease
Instruments and platforms
- Ambr 250
- ÄKTA pure
- ÄKTA avant
- ÄKTA pcc
- Beckman Biomek i5 workstation
- ÄKTA process
3 more
- ÄKTA ready
- Tecan
- LabChip
Modalities and species
- Modalities
- Antibody
- Bispecific
- ADC
- Recombinant protein
- Species and models
- Mammalian cell culture
- CHO-K1
- CHO-S
- CHO-K1 GS-KO
Certifications
As the company states them, with the certificate or registry record where there is one.
GMPSelf-reported
Scope: drug substance manufacturing, drug product manufacturing, clinical and commercial production
Company
- Type
- CDMO
- Founded
- 2022
- Team
- 1.2K+ Highly Skilled Employees
Locations
- Based in
- Hangzhou, China
- Sites
- Suzhou, China
- Serves
- Global